Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein.
about
The molecular mechanism behind resistance of the kinase FLT3 to the inhibitor quizartinib.Clinical significance of detecting CSF-derived tumor cells in breast cancer patients with leptomeningeal metastasis.Computer simulations of the signalling network in FLT3 +-acute myeloid leukaemia - indications for an optimal dosage of inhibitors against FLT3 and CDK6.
P2860
Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Palbociclib can overcome mutat ...... ween the drug and the protein.
@en
Palbociclib can overcome mutat ...... ween the drug and the protein.
@nl
type
label
Palbociclib can overcome mutat ...... ween the drug and the protein.
@en
Palbociclib can overcome mutat ...... ween the drug and the protein.
@nl
prefLabel
Palbociclib can overcome mutat ...... ween the drug and the protein.
@en
Palbociclib can overcome mutat ...... ween the drug and the protein.
@nl
P2093
P2860
P356
P1433
P1476
Palbociclib can overcome mutat ...... ween the drug and the protein.
@en
P2093
Julio Zukerman Schpector
Patrizia Jensen
Stefan Fröhling
Stella Hernandez Maganhi
P2860
P304
P356
10.1002/PRO.3135
P577
2017-02-07T00:00:00Z